Dive Brief:
- Teleflex will close a manufacturing facility in Maple Grove, Minnesota, by next March and cut more than 100 employees as a result.
- The planned closure will affect an expected 101 positions, according to a Tuesday Worker Adjustment and Retraining Notification filing obtained by MedTech Dive. The Minnesota Star Tribune first reported the cuts.
- Most laboratory and manufacturing operations are expected to cease by June 30, with the layoffs occurring on July 1, according to the filing. Teleflex did not respond to a request for comment on why it was closing the Maple Grove facility.
Dive Insight:
In February, Teleflex announced it would split into two separate, public entities. A new company would comprise Teleflex’s urology, acute care and OEM businesses, while the remaining company would include the vascular access, interventional and surgical businesses. Simultaneously, Teleflex bought Biotronik’s vascular intervention division.
Teleflex aims to streamline manufacturing during the restructuring. The company aims to reduce the number of facilities from the combination of Biotronik and the remaining company from 19 facilities to seven, CEO Liam Kelly told investors in February.
The Maple Grove site was used to make diagnostic and interventional catheters, according to the company’s website. Teleflex’s remaining company had pro forma revenue of $2.1 billion in 2024 with the Biotronik acquisition.
